Dr. Jing L. Marantz
Jing L. Marantz has over 25 years of experience in the biopharmaceutical industry spanning R&D, medical affairs, business development, and portfolio strategy. She currently serves as EVP, Chief Medical Officer of Intellia Therapeutics. Before Intellia, Jing was Chief Medical Officer at Scholar Rock, where she led the development organization in advancing multiple clinical programs across neuromuscular, oncology and obesity, culminating in the FDA approval of ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy. During her tenure at Scholar Rock, she led simultaneous regulatory submissions to the FDA and EMA followed by successful engagement with the PMDA, enabling JNDA submission without Japanese data. Prior to Scholar Rock, Jing has held leadership positions at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals, playing key roles in the development and commercialization of over a dozen products across hematology/oncology, neurology, and rare diseases. Earlier in her career, she was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. Jing is a member of the Board of Directors for Arcturus Therapeutics, Inc (NASDAQ: ARCT). She received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.